Human Genome Sciences sees positive results for lupus drug Nov 3, 2009
Belgium-based UCB SA and partner Immunomedics Inc., based in Morris Plains, N.J., said in August that its experimental lupus drug performed well in its second stage of human studies and they planned to launch the third and final phase of trials next year. And in Human Genome Sciences back yard, MedImmune LLC last announced in August 2008 that it was enrolling lupus patients for the second phase of clinical studies of its own lupus drug candidate. (Washington Business Journal, DC)
Stocks Turn Losses To Gains Aug 29, 2009
Shares fell on news that a co-developed lupus drug from rivals Immunomedics () and UCB showed promise. Elsewhere, Frontline () and Tiffany & Co. () are the only two firms reporting earnings on Friday. (Investors Business Daily)
Human Genome takes hit over rival results Aug 28, 2009
But the study results, while lifting Immunomedics (NASDAQ: IMMU) stock by 60 percent by noon Thursday, caused HGS stock prices to deflate by 8 percent, to $18 ... In both of its trials, HGS used a different measurement than Immunomedics relied on for its main assessment of Benlysta s effectiveness. (Washington Business Journal, DC)
UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE) Aug 27, 2009
Source: Immunomedics, Inc. ... BRUSSELS, Belgium and MORRIS PLAINS, N.J., Aug. 27, 2009 (GLOBE NEWSWIRE) -- UCB and Immunomedics (Nasdaq: - ) announced today top-line results from UCB's phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus) ... Epratuzumab, developed by Immunomedics and licensed to UCB for all autoimmune disease indications in 2006, is a humanized anti-CD22 monoclonal antibody with the potential... (Primezone Releases)
Novel Targeted Radiation Therapy From Immunomedics Produces Objective Responses in Pancreatic Cancer Jun 1, 2009
Press Release Source: Immunomedics, Inc. ... May 31, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM: - ), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported a 30% objective response rate in 10 evaluable patients with inoperable, advanced pancreatic cancer treated with a novel targeted radiation therapy developed by the Company in combination with gemcitabine ... Immunomedics is a New Jersey-based... (Primezone Releases)
Immunomedics Reports Updated Results of Milatuzumab in Dose-Escalation Study for Multiple Myeloma May 31, 2009
Press Release Source: Immunomedics, Inc. ... May 30, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM: - ), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that milatuzumab, the Company's proprietary humanized anti-CD74 antibody, produced disease stabilization in some patients with multiple myeloma and is well tolerated at doses up to 16 ... Immunomedics is a New Jersey-based biopharmaceutical company... (Primezone Releases)
Smokers' Lung Treatment May Fail to Fire Up Bidders as Nycomed Seeks Buyer Apr 9, 2009
The Swiss company, which also offers medicines to treat asthma, pain and inflammatory diseases as well as over-the- counter drugs, bought rights to an experimental rheumatoid arthritis therapy from Immunomedics Inc. last year. In January, it purchased a license to sell an effervescent version of the Alendronate osteoporosis treatment from Florida-based EffRx Inc.. (Bloomberg -- Europe)
Report: Swiss Drugmaker Nycomed Shopping Itself Mar 24, 2009
Nycomed licenses the heartburn drug Protonix to Wyeth in the U.S. Nycomed also has partnerships with NPS Pharmaceuticals Inc., Immunomedics Inc., Sepracor Inc., Micromet Inc. and Baxter International Inc., among others. Copyright 2009 The Associated Press. (ABC News -- Wire)
